Lantheus (LNTH)

• Market cap: $6.21B
• 1 day: -2.89%
• 5 days: -3.70%
• 1 month: 3.27%
• 3 months: -18.87%
• 6 months: 9.57%
• Year to date: 41.49%
• 1 year: 53.38%
• 5 years: 331.10%
• 10 years: 1,218.76%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Employees: 834

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

69% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 61

67% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]

60% more call options, than puts

Call options by funds: $93.8M | Put options by funds: $58.8M

38% more capital invested

Capital invested by funds: $5.54B [Q2] → $7.65B (+$2.12B) [Q3]

9% more funds holding

Funds holding: 449 [Q2] → 491 (+42) [Q3]

1.16% more ownership

Funds ownership: 99.56% [Q2] → 100.72% (+1.16%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 178

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $112 25% upside
• Avg. target: $125 40% upside
• High target: $143 60% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Goldman Sachs Paul Choi 40% 1-year accuracy 4 / 10 met price target	60% upside $143	Buy Initiated	18 Dec 2024
Truist Securities Richard Newitter 80% 1-year accuracy 40 / 50 met price target	34% upside $120	Buy Reiterated	8 Nov 2024
JMP Securities David Turkaly 29% 1-year accuracy 7 / 24 met price target	25% upside $112	Market Outperform Maintained	7 Nov 2024